# Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC

> **NCT06448910** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fudan University** · enrollment: 41 (estimated)

## Conditions studied

- NSCLC
- Locally Advanced Lung Carcinoma

## Interventions

- **DRUG:** Cadonilimab (AK104)

## Key facts

- **NCT ID:** NCT06448910
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2025-10
- **Final completion:** 2027-06
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06448910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06448910, "Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06448910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*